flâneur

Harnessing Real-World Data for Regulatory Use and Applying Innovative Applications - PMC

ncbi.nlm.nih.gov · 5,689 words · saved by 1 readers

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 1Research, Development and Medical, Upjohn Division, Pfizer Inc, New York, NY, 10017, USA 2Research, Development and Medical, Upjohn Division, Pfizer Inc, San Diego, CA, 92121, USA 3Business Technology, Upjohn Division, Pfizer Inc, New York, NY, 10017, USA 4Research, Development and Medical, Pfizer Gulf FZ LLC, Dubai Media City, United Arab Emirates 5Business Technology, Upjohn Division, Pfizer Inc, Collegeville, PA, 19426, USA 6Envision Pharma Group, Envision House, Horsham, RH12 1XQ, UK 7Research, Development and Medical, Upjohn Division, Pf

Abstract A vast quantity of real-world data (RWD) are available to healthcare researchers. Such data come from diverse sources such as electronic health records, insurance claims and billing activity, product and disease registries, medical devices used in the home, and applications on mobile devices. The analysis of RWD produces real-world evidence (RWE), which is clinical evidence that provides information about usage and potential benefits or risks of a drug. This review defines and explains RWD, and it also details how regulatory authorities are using RWD and RWE. The main challenges in…

related reading